• español
    • English
  • English 
    • español
    • English
  • Login
View Item 
  •   DSpace Home
  • Producción Científica
  • Artículos, capítulos, libros...UCO
  • View Item
  •   DSpace Home
  • Producción Científica
  • Artículos, capítulos, libros...UCO
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice

Thumbnail
View/Open
jcm-08-01549.pdf (764.0Kb)
Author
Biagetti, Betina
Herance, J.R.
Ferrer, Roser
Aulinas, Anna
Palomino-Schätzlein, Martina
Mesa, Jordi
Castaño, Justo P.
Luque, Raúl M.
Simó, Rafael
Publisher
MDPI
Date
2019
Subject
Acromegaly
Metabolomics
Amino acids
Branched chain
Insulin resistance
Muscular weakness
METS:
Mostrar el registro METS
PREMIS:
Mostrar el registro PREMIS
Metadata
Show full item record
Abstract
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. The present study was aimed at identifying metabolites that could be used as biomarkers for a better disease phenotyping. For this purpose, metabolic fingerprint using an untargeted metabolomic approach was examined in serum from 30 patients with acromegaly and 30 age-matched controls. Patients with acromegaly presented fewer branched-chain amino acids (BCAAs) compared to the control group (valine: 4.75 ± 0.87 vs. 5.20 ± 1.06 arbitrary units (AUs), p < 0.05; isoleucine: 2.54 ± 0.41 vs. 2.80 ± 0.51 AUs; p < 0.05). BCAAs were also lower in patients with active disease compared to patients with normal levels of IGF-1 with or without medical treatment. GH, but not IGF-1, serum levels were inversely correlated with both valine and isoleucine. These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator. In addition, our results suggest that the assessment of BCAAs could help to identify active disease and to monitor the response to therapeutic strategies.
URI
http://hdl.handle.net/10396/19008
Fuente
Journal of Clinical Medicine 8(10), 1549 (2019)
Versión del Editor
http://dx.doi.org/10.3390/jcm8101549
Collections
  • DBCFI-Artículos, capítulos...
  • Artículos, capítulos, libros...UCO

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
© Biblioteca Universidad de Córdoba
Biblioteca  UCODigital
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics

De Interés

Archivo Delegado/AutoarchivoAyudaPolíticas de Helvia

Compartir


DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
© Biblioteca Universidad de Córdoba
Biblioteca  UCODigital